ArticleInternational urology and nephrology2026
Outcome of combined triamcinolone and platelet-rich plasma injection in treatment of patients with interstitial cystitis/bladder pain syndrome.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTreatment of interstitial cystitis/bladder pain syndrome (IC/BPS) often lacks durable efficacy. Intravesical platelet-rich plasma (PRP) achieves > 50% success rates, but some patients remain refractory. This study evaluated the outcome of combined triamcinolone and PRP in patients with suboptimal response to prior PRP therapy.
methodsSixty-two patients with IC/BPS and inadequate response (global response assessment [GRA] <2) to previous PRP injections at least 3 months earlier were included. All patients received four monthly intravesical injections of PRP combined with 40 mg triamcinolone. Changes in symptom scores and uroflowmetry parameters were assessed from baseline to 3 and 6 months after treatment and compared with prior post-PRP treatment outcomes.
resultsThe cohort included 15 patients with Hunner's IC (HIC) and 47 with non-Hunner's IC (NHIC). After treatment, symptom scores and bladder pain improved significantly, with 33 patients (53.2%) achieving GRA ≥2 at 3 months and 38 (61.3%) at 6 months after completion of combined treatment. Compared with prior PRP post-treatment outcome, combined therapy resulted in greater symptom improvement. Patients with NHIC and HIC demonstrated similar treatment outcome and reductions in bladder pain. Within the NHIC subgroup, patients with different cystoscopic hydrodistention findings at baseline showed similar symptomatic improvement with combined therapy. However, patients with a higher baseline bladder pain score (visual analog score ≥5) had a less favorable GRA at 3 months.
conclusionCombined PRP and triamcinolone intravesical injections achieved a satisfactory treatment outcome in 61.3% of patients with IC/BPS who were refractory to previous PRP treatment, suggesting a potential role for adjunctive steroid therapy targeting inflammation.
Indexed as
Identifiers
42732484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.